BR9907228A - Uso de uma proteìna de choque térmico, processo para proteger um mamìfero de uma doença, formulação para proteger um mamìfero de desenvolver uma doença, uso de uma molécula de ácido nucleico, e processo para prescrever um tratamento para hiper-sensibilidade das vias aéreas ou limitação do fluxo de ar associado com uma doença envolvendo resposta inflamatória - Google Patents
Uso de uma proteìna de choque térmico, processo para proteger um mamìfero de uma doença, formulação para proteger um mamìfero de desenvolver uma doença, uso de uma molécula de ácido nucleico, e processo para prescrever um tratamento para hiper-sensibilidade das vias aéreas ou limitação do fluxo de ar associado com uma doença envolvendo resposta inflamatóriaInfo
- Publication number
- BR9907228A BR9907228A BR9907228-9A BR9907228A BR9907228A BR 9907228 A BR9907228 A BR 9907228A BR 9907228 A BR9907228 A BR 9907228A BR 9907228 A BR9907228 A BR 9907228A
- Authority
- BR
- Brazil
- Prior art keywords
- disease
- protect
- mammal
- treatment
- shock protein
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 8
- 238000000034 method Methods 0.000 title abstract 7
- 241000124008 Mammalia Species 0.000 title abstract 4
- 238000009472 formulation Methods 0.000 title abstract 3
- 230000028709 inflammatory response Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 102000002812 Heat-Shock Proteins Human genes 0.000 title abstract 2
- 108010004889 Heat-Shock Proteins Proteins 0.000 title abstract 2
- 206010020751 Hypersensitivity Diseases 0.000 title abstract 2
- 208000026935 allergic disease Diseases 0.000 title abstract 2
- 230000009610 hypersensitivity Effects 0.000 title abstract 2
- 102000039446 nucleic acids Human genes 0.000 title abstract 2
- 108020004707 nucleic acids Proteins 0.000 title abstract 2
- 150000007523 nucleic acids Chemical class 0.000 title abstract 2
- 206010014950 Eosinophilia Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000035939 shock Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Ophthalmology & Optometry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1233098A | 1998-01-23 | 1998-01-23 | |
| PCT/US1999/001421 WO1999037319A1 (en) | 1998-01-23 | 1999-01-22 | Method for treating inflammatory diseases using heat shock proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9907228A true BR9907228A (pt) | 2000-10-24 |
Family
ID=21754459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9907228-9A BR9907228A (pt) | 1998-01-23 | 1999-01-22 | Uso de uma proteìna de choque térmico, processo para proteger um mamìfero de uma doença, formulação para proteger um mamìfero de desenvolver uma doença, uso de uma molécula de ácido nucleico, e processo para prescrever um tratamento para hiper-sensibilidade das vias aéreas ou limitação do fluxo de ar associado com uma doença envolvendo resposta inflamatória |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20020006410A1 (enExample) |
| EP (1) | EP1049483A1 (enExample) |
| JP (1) | JP2002509074A (enExample) |
| KR (1) | KR20010040389A (enExample) |
| CN (1) | CN1324243A (enExample) |
| AU (1) | AU2337499A (enExample) |
| BR (1) | BR9907228A (enExample) |
| CA (1) | CA2318263A1 (enExample) |
| CZ (1) | CZ20002669A3 (enExample) |
| HU (1) | HUP0100241A2 (enExample) |
| IL (1) | IL137404A0 (enExample) |
| NO (1) | NO20003775L (enExample) |
| PL (1) | PL342166A1 (enExample) |
| TR (1) | TR200002973T2 (enExample) |
| WO (1) | WO1999037319A1 (enExample) |
| ZA (1) | ZA99499B (enExample) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7992572B2 (en) | 1998-06-10 | 2011-08-09 | Asthmatx, Inc. | Methods of evaluating individuals having reversible obstructive pulmonary disease |
| WO2000048622A2 (en) * | 1999-02-22 | 2000-08-24 | University Of Iowa Research Foundation | Method for inhibiting inflammatory responses |
| WO2001022816A1 (en) * | 1999-09-30 | 2001-04-05 | National Jewish Medical And Research Center | MODULATION OF ηδ T CELLS TO REGULATE AIRWAY HYPERRESPONSIVENESS |
| US6737398B1 (en) | 1999-09-30 | 2004-05-18 | National Jewish Medical And Research Center | Modulation of γδ T cells to regulate airway hyperresponsiveness |
| US7235649B2 (en) * | 2000-03-24 | 2007-06-26 | Duke University | Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same |
| GB0028122D0 (en) * | 2000-11-17 | 2001-01-03 | St Georges Entpr Ltd | Method |
| AUPR381601A0 (en) * | 2001-03-19 | 2001-04-12 | Monash University | Method of treating respiratory conditions |
| CA2460396A1 (en) * | 2001-10-01 | 2003-04-10 | Duke University | Isolated grp94 ligand binding domain polypeptide and nucleic acid encoding same, crystalline form of same, and screening methods employing same |
| AU2003216288B2 (en) * | 2002-02-13 | 2009-09-24 | Duke University | Modulation of immune response by non-peptide binding stress response polypeptides |
| KR100615389B1 (ko) * | 2002-08-23 | 2006-08-25 | (주)헬릭서 | 다래 추출물을 함유하는 알러지성 질환 및 비알러지성염증 질환의 예방 및 개선용 건강 기능 식품 |
| US20100111927A1 (en) * | 2002-08-23 | 2010-05-06 | Sunyoung Kim | Compositions Comprising Actinidia and Methods of Use Thereof |
| GB0226105D0 (en) * | 2002-11-08 | 2002-12-18 | St Georges S Entpr Ltd | Pain relief agents |
| EP1951282A4 (en) * | 2005-10-20 | 2009-09-02 | Cbio Ltd | TREATMENT OF HYPERSENSITIVITY |
| KR100768265B1 (ko) * | 2005-11-10 | 2007-10-17 | 한국화학연구원 | 혈액내 순환시간을 향상시키기 위한 헤파린이 수식된리포솜 및 이의 제조방법 |
| PL2659904T3 (pl) | 2008-06-26 | 2016-01-29 | Orphazyme Aps | Zastosowanie Hsp70 jako regulatora aktywności enzymatycznej |
| EP2391229B1 (en) | 2009-01-29 | 2015-07-15 | Alfa Biogene International B.V. | Functional food product comprising heat shock protein or a hydrolysate thereof from alfalfa |
| EP2397074B1 (en) | 2010-06-19 | 2012-10-24 | M Stenqvist AB | A system and computer readable medium for determination of transpulmonary pressure in a patient connected to a breathing apparatus |
| DK2646044T3 (da) | 2010-11-30 | 2019-11-25 | Orphazyme As | Metoder til at øge den intracellulære aktivitet af Hsp70 |
| WO2012097255A2 (en) * | 2011-01-14 | 2012-07-19 | Scott & White Healthcare | Therapeutic effect of heat shock proteins in preventing amylin aggregation in type 2 diabetes mellitus |
| WO2012154967A1 (en) | 2011-05-12 | 2012-11-15 | Proteostasis Therapeutics, Inc. | Proteostasis regulators |
| WO2012174549A2 (en) * | 2011-06-16 | 2012-12-20 | Children's Hospital Medical Center | Blockade of eosinophil production by toll-like receptors |
| US10034915B2 (en) | 2011-06-23 | 2018-07-31 | The Board Of Trustees Of The Leland Stanford Junior University | Small heat shock proteins and active fragments thereof as a therapy for inflammation and ischemia |
| JP2015504919A (ja) | 2012-01-25 | 2015-02-16 | プロテオステイシス セラピューティクス，インコーポレイテッド | プロテアソーム活性を調節する化合物 |
| KR20250069686A (ko) | 2014-09-15 | 2025-05-19 | 제브라 덴마크 에이/에스 | 아리모클로몰 제제 |
| EP3402572B1 (en) | 2016-01-13 | 2022-03-16 | Children's Hospital Medical Center | Compositions and methods for treating allergic inflammatory conditions |
| US10898476B2 (en) | 2016-04-13 | 2021-01-26 | Orphazyme A/S | Heat shock proteins and cholesterol homeostasis |
| LT3448382T (lt) | 2016-04-29 | 2021-04-12 | Orphazyme A/S | Arimoklomolis, skirtas su gliukocerebrozidaze susijusiems sutrikimams gydyti |
| CN106220718B (zh) * | 2016-08-04 | 2019-12-10 | 上海市农业科学院 | 一种草菇热激蛋白VvHSP60及其应用 |
| CN106243203B (zh) * | 2016-08-04 | 2019-12-10 | 上海市农业科学院 | 一种草菇热激蛋白VvHSP70及其应用 |
| US11859250B1 (en) | 2018-02-23 | 2024-01-02 | Children's Hospital Medical Center | Methods for treating eosinophilic esophagitis |
| EP3781588B1 (en) | 2018-04-20 | 2024-10-30 | Children's Hospital Medical Center | Blood biomarker for eosinophilic gastrointestinal disorders |
| BR122023023216A2 (pt) | 2018-06-27 | 2024-02-20 | Proteostasis Therapeutics, Inc. | Compostos, composição farmacêutica e uso de uma quantidade eficaz de um composto |
| CN112585130A (zh) | 2018-06-27 | 2021-03-30 | 蛋白质平衡治疗股份有限公司 | 蛋白酶体活性增强化合物 |
| US12297501B2 (en) | 2019-02-25 | 2025-05-13 | Children's Hospital Medical Center | Methods for diagnosing and treating eosinophilic gastritis |
| US20230416224A1 (en) | 2020-11-19 | 2023-12-28 | Zevra Denmark A/S | Processes for preparing arimoclomol citrate and intermediates thereof |
| CN114046596B (zh) * | 2021-11-17 | 2022-09-23 | 重庆大学 | 基于trp生化指标检测的室内空气质量控制系统及方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5348945A (en) * | 1990-04-06 | 1994-09-20 | Wake Forest University | Method of treatment with hsp70 |
| DE69126668T2 (de) * | 1990-11-08 | 1997-10-23 | University College London, London | Mycobacterium als adjuvans für antigene |
| GB9211736D0 (en) * | 1992-06-03 | 1992-07-15 | Univ Cardiff | Allergic treatment |
| EP0941315B1 (en) * | 1996-11-26 | 2006-03-01 | Stressgen Biotechnologies Corporation | Fusion proteins containing stress proteins for inducing immune responses |
-
1999
- 1999-01-22 BR BR9907228-9A patent/BR9907228A/pt not_active IP Right Cessation
- 1999-01-22 WO PCT/US1999/001421 patent/WO1999037319A1/en not_active Ceased
- 1999-01-22 PL PL99342166A patent/PL342166A1/xx not_active Application Discontinuation
- 1999-01-22 KR KR1020007008033A patent/KR20010040389A/ko not_active Withdrawn
- 1999-01-22 ZA ZA9900499A patent/ZA99499B/xx unknown
- 1999-01-22 EP EP99903321A patent/EP1049483A1/en not_active Withdrawn
- 1999-01-22 CZ CZ20002669A patent/CZ20002669A3/cs unknown
- 1999-01-22 AU AU23374/99A patent/AU2337499A/en not_active Abandoned
- 1999-01-22 JP JP2000528300A patent/JP2002509074A/ja active Pending
- 1999-01-22 TR TR2000/02973T patent/TR200002973T2/xx unknown
- 1999-01-22 IL IL13740499A patent/IL137404A0/xx unknown
- 1999-01-22 HU HU0100241A patent/HUP0100241A2/hu unknown
- 1999-01-22 CA CA002318263A patent/CA2318263A1/en not_active Abandoned
- 1999-01-22 CN CN99804346A patent/CN1324243A/zh active Pending
-
2000
- 2000-07-21 NO NO20003775A patent/NO20003775L/no not_active Application Discontinuation
-
2001
- 2001-08-17 US US09/932,483 patent/US20020006410A1/en not_active Abandoned
-
2006
- 2006-09-25 US US11/534,782 patent/US20070179087A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN1324243A (zh) | 2001-11-28 |
| EP1049483A1 (en) | 2000-11-08 |
| HUP0100241A2 (hu) | 2001-06-28 |
| PL342166A1 (en) | 2001-05-21 |
| CA2318263A1 (en) | 1999-07-29 |
| CZ20002669A3 (cs) | 2001-11-14 |
| US20070179087A1 (en) | 2007-08-02 |
| IL137404A0 (en) | 2001-07-24 |
| JP2002509074A (ja) | 2002-03-26 |
| ZA99499B (en) | 1999-07-22 |
| AU2337499A (en) | 1999-08-09 |
| TR200002973T2 (tr) | 2001-02-21 |
| WO1999037319A1 (en) | 1999-07-29 |
| US20020006410A1 (en) | 2002-01-17 |
| NO20003775L (no) | 2000-09-22 |
| KR20010040389A (ko) | 2001-05-15 |
| NO20003775D0 (no) | 2000-07-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9907228A (pt) | Uso de uma proteìna de choque térmico, processo para proteger um mamìfero de uma doença, formulação para proteger um mamìfero de desenvolver uma doença, uso de uma molécula de ácido nucleico, e processo para prescrever um tratamento para hiper-sensibilidade das vias aéreas ou limitação do fluxo de ar associado com uma doença envolvendo resposta inflamatória | |
| ES2150496T3 (es) | Cicloalquilimidazopiridinas condensadas. | |
| CY1110505T1 (el) | Ανθρωπινα αντισωματα dr4 και χρησεις αυτων | |
| ATE380037T1 (de) | Verfaheren zur durch rekombinante adeno- assoziierte virus-gerichtete gentherapie | |
| ES2149276T3 (es) | Imidazo(4,5-c)piridin-4-aminas. | |
| DE69201441D1 (de) | Erreger der mysteriösen schweinekrankheit,impfstoff-zusammensetzungen und diagnose kits. | |
| BR0014214A (pt) | Imidazoquinolinas substituìdas com amida | |
| DK382786D0 (da) | Overfladeaktivt rekombinant-alveolarprotein | |
| BR0213303A (pt) | Proteìnas de ligação de alvejamento direto | |
| BR0210216A (pt) | Holotoxina do cólera imunogênica, mutante (ct-crm), composição imunogênica, métodos para aumentar a resposta imune de um hospedeiro vertebrado a um antìgeno, e para produzir uma holotoxina do cólera imunogênica, mutante, sequência ou molécula de ácido nucleico isolado e purificado, célula hospedeira, e, uso de uma holotoxina do cólera mutante | |
| CY1109151T1 (el) | Αντισωματα dr4 και χρησεις αυτων | |
| BR0208041A (pt) | Interferon beta modificado com imunogenicidade reduzida | |
| EP2277889A3 (en) | Fusion proteins of albumin and interferon beta | |
| BR0213940A (pt) | Análogos de lipoxina a4 | |
| BR9711457A (pt) | Compostos e processo para o tratamento e diagnóstico de infecções micobacterianas. | |
| BRPI0407533A (pt) | proteìnas de fusão e muteìnas do interferon alfa com propriedades melhoradas | |
| BR9607628A (pt) | Mólecula proteinácea biologicamente isolada, molécula recombinante, fragmento de peptìdeo, molécula de ácido nucleico, composição farmacêutica, e, processos para preparar uma molécula recombinante e para induzir a proliferação astroglial em um mamìfero | |
| BR0207014A (pt) | Antagonista de receptor de interleucina-1 modificada (il-1ra) com imunogenicidade reduzida. | |
| BR0207018A (pt) | Leptina modificada com imunogenicidade reduzida | |
| BR0207015A (pt) | Eritropoientina modificada (epo) com imunogenicidade reduzida | |
| DE60037978D1 (de) | Interferon ähnliche moleküle, und deren verwendungen | |
| BR0016129A (pt) | Molécula de ácido nucléico, vetor recombinante, polipeptìdeo, racemase de aminoácido eucariótica, anticorpos, célula hospedeira, métodos para produzir polipeptìdeo, para detectar um parasita e uma proteìna eucariótica, para triar moléculas ativas, para detectar e quantificar a presença ou a ausência de uma sequência, para inibir uma proteìna eucariótica, para produzir uma racemase de aminoácido recombinante eucariótica e d-aminoácio e para prevenir ou inibir infecção, plasmìdeo, complexo imunológico, kit para detectar um parasita, fragmento de um polinucleotìdeo, proteìna eucariótica, processos para preparar uma proteìna eucariótica purificada, para detectar uma infecção e para infecção e para triar uma molécula, composição imunizadora, composição de vacina, qualquer modificação molecular do gene ou de um fragmento do gene, uso de qualquer modificação molecular ou bioquìmica da atividade enzimática da racemase, e, qualquer molécula ou composto | |
| BR0207704A (pt) | Alfa interferon modificado com imunogenicidade reduzida | |
| BR0016419A (pt) | Método para o aumento das respostas de imunização com relação a vacina do vìrus do herpes simplex | |
| BR0207905A (pt) | Protamina modificada com imunogenicidade reduzida |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A, 6A, 7A E 8A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1910 DE 14/08/2007. |